Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Small molecule inhibitors for CLL: which to use, sequencing, switching and combinations

Susan O’Brien • 9 Dec 2017
ASH 2017
Chronic Lymphocytic Leukemia Ibrutinib Idelalisib Venetoclax

There are now three small molecule inhibitors to choose from for the treatment of chronic lymphocytic leukemia (CLL): Ibrutinib, idelalisib and venetoclax. In this video, Susan O’Brien, MD, of the University of California, Irvine, CA, discusses the indications and reasoning for which to use, switching between them and sequencing. Prof. O’Brien also covers combining these agents with one other and antibodies, in addition to resistance. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

More from Susan O’Brien

2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien • 14 Jun 2019
2:19
CAR T-cell therapy updates in CLL
Susan O’Brien • 14 Jun 2019
2:00
CLL RESONATE-2: Five-year follow-up
Susan O’Brien • 13 Jun 2019
3:19
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
Susan O’Brien • 15 Jun 2019

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals